Ovarian TumorMACS™ Medium is an optimized serum-free cell culture medium for the cultivation and expansion of tumor cells from primary and xenotransplanted ovarian tumors. It enables the establishment of stable cell lines from freshly dissociated tumor tissue.
The medium supports the transition of tumor cells into physiologically relevant 3D culture formats, including tumor organoids and tumoroids.
Related products for Ovarian TumorMACS™ Medium, human
Ovarian TumorMACS™ Medium is an optimized serum-free cell culture medium for the cultivation and expansion of tumor cells from primary and xenotransplanted ovarian tumors. It enables the establishment of stable cell lines from freshly dissociated tumor tissue.
The medium supports the transition of tumor cells into physiologically relevant 3D culture formats, including tumor organoids and tumoroids.
The Ovarian TumorMACS™ Medium is an optimized and standardized medium for the reliable expansion of specific tumor cells from primary or xenotransplanted human ovarian tumor samples.
Tumor cells from freshly dissociated tissue can be cultured over multiple passages, allowing for in vitro assays, such as drug screenings on primary cell cultures or characterization studies including gene expression or protein profiling. In addition, the Ovarian TumorMACS Medium supports the establishment of new cell lines and thereby obtaining sufficient cell numbers for further experiments, such as in vivo transplantation studies in animals. Ovarian TumorMACS Medium efficiently expands cultures of specific primary ovarian tumor cells in vitro while maintaining the cell populations’ heterogeneity and tumorigenic potential.
The medium is manufactured under strictly controlled conditions using ingredients of the highest quality. Ovarian TumorMACS Medium offers consistent lot-to-lot performance and optimal conditions for the cultivation of specific primary ovarian tumor cells.
Cell lines derived from primary tumors and propagated in Ovarian TumorMACS Medium retained their initial heterogeneity and closely and reliably resemble the initial patient tumor.
- Labrosse, K. B. et al. (2024) Protocol for quantifying drug sensitivity in 3D patient-derived ovarian cancer models. STAR Protoc : doi.org/10.1016/j.xpro.2024.103274
- Labrosse, K. B. et al. (2026) Ex vivo drug sensitivity testing predicts treatment outcomes in advanced ovarian cancer. NPJ Precis Oncol. : doi.org/10.1038/s41698-026-01321-4
- Kmiecik, S. W. et al. (2025) Validation of a UPLC-MS/MS Method for Quantifying Intracellular Olaparib Levels in Resistant Ovarian Cancer Cells. Pharmaceuticals (Basel) : doi: 10.3390/ph18121870
- Sensi, F. et al. (2025) Patient-derived extracellular matrix from decellularized high-grade serous ovarian carcinoma tissues as a biocompatible support for organoid growth. Transl Oncol. 13 (61): 1025232-461
- Estermann, M. et al. (2023) A 3D multi-cellular tissue model of the human omentum to study the formation of ovarian cancer metastasis. Biomaterials : doi.org/10.1016/j.biomaterials.2023.121996
You have previously chosen International as your location.
What do you want to do?